How AI-supported intelligent systems support infection prevention and control training in healthcare: A systematic review of educational functions and outcomes.

Nurse Educ TodayJul 30, 2026 (epub)
Clinical ResearchInfectious Diseases

Ha-Young Park, Yoojin Kim

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the role of AI-supported intelligent systems in infection prevention and control (IPC) education, analyzing 18 studies. The findings indicate that these systems primarily enhance short-term compliance, focusing on hand hygiene through automated monitoring and feedback. However, their effectiveness in fostering sustained IPC competence remains limited.

Key findings

  • Most systems emphasized hand hygiene and used fully automated monitoring for behavior capture.
  • Educational functions were mainly performance assessment, automated feedback, and reminders.
  • Outcomes primarily measured compliance or performance metrics, with limited assessment of sustained behavioral change.

Why it matters

Understanding the effectiveness of AI-supported systems in IPC training is crucial for developing educational strategies that ensure long-term competence in healthcare settings, ultimately improving patient safety and infection control.

Source

PubMed · PMID 42556208

Published in Nurse Educ Today. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.